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pulmonary tuberculosis: a systematic
review and meta-analysis
Priya B. Shete1,2*† , Katherine Farr1,2†, Luke Strnad3, Christen M. Gray4 and Adithya Cattamanchi1,2
Abstract
Background: The need for a rapid, molecular test to diagnose tuberculosis (TB) has prompted exploration of TB-LAMP
(Eiken; Tokyo, Japan) for use in resource-limited settings. We conducted a systematic review to assess the accuracy of
TB-LAMP as a diagnostic test for pulmonary TB.
Methods: We analyzed individual-level data for eligible patients from all studies of TB-LAMP conducted between Jan
2012 and October 2015 to compare the diagnostic accuracy of TB-LAMP with that of smear microscopy and Xpert
MTB/RIF® using 3 reference standards of varying stringency. Pooled sensitivity and specificity and pooled differences in
sensitivity and specificity were estimated using random effects meta-analysis. Study quality was evaluated using
QUADAS-2.
Results: Four thousand seven hundred sixty individuals across 13 studies met eligibility criteria. Methodological quality
was judged to be low for all studies. TB-LAMP had higher sensitivity than sputum smear microscopy (pooled sensitivity
difference + 13·2, 95% CI 4·5–21·9%) and similar sensitivity to Xpert MTB/RIF (pooled sensitivity difference − 2·5, 95% CI
-8·0 to + 2·9) using the most stringent reference standard available. Specificity of TB-LAMP was similar to that of
sputum smear microscopy (pooled specificity difference − 1·8, 95% CI -3·8 to + 0·2) and Xpert MTB/RIF (pooled
specificity difference 0·5, 95% CI -0·9 to + 1·8).
Conclusions: From the perspective of diagnostic accuracy, TB-LAMP may be considered as an alternative test for
sputum smear microscopy. Additional factors such as cost, feasibility, and acceptability in settings that continue
to rely on sputum smear microscopy should be considered when deciding to adopt this technology. Xpert MTB/
RIF should continue to be preferred in settings where resource and infrastructure requirements are adequate and
where HIV co-infection or drug-resistance is of concern.
Keywords: Tuberculosis, Diagnostic testing, Molecular assay, Point of care
Background
Better diagnostics are essential for achieving global
tuberculosis (TB) elimination targets. In 2013, Xpert
MTB/RIF® (Xpert) (Cepheid, Sunnyvale, CA, USA) be-
came the first molecular TB test endorsed by the
World Health Organization (WHO), and there has
since been considerable investment in its scale-up [1].
However, relatively high device and consumable costs,
infrastructure requirements, and need for continuous
instrument maintenance remain obstacles to use of
Xpert as a point-of-care test in peripheral health cen-
ters where the majority of TB patients initially
present for care.
To expand the availability of molecular testing for TB,
Eiken Chemical Co., Ltd. developed a commercial ver-
sion of loop-mediated isothermal amplification (LAMP),
a technique in which nucleic acid amplification occurs
under isothermal conditions. LAMP is based on
auto-cycling, strand displacement DNA synthesis
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performed by a DNA polymerase with high strand
displacement activity and two specially designed
inner and two outer primers [2, 3]. Eiken’s Loopamp
MTBC Detection Kit (TB-LAMP) targets the gyrB
and IS regions of the Mycobacterium tuberculosis
(MTB) complex genome. Detection of amplified
product is based on turbidity visualized with the
naked eye or under ultraviolet (UV) light after 15–
60 min [4–7].
To inform WHO guideline development, we con-
ducted a systematic review of studies evaluating the
diagnostic accuracy of TB-LAMP using the latest
assay kit and protocol. The primary objective was to
evaluate the diagnostic accuracy of TB-LAMP if used
as an alternative test for sputum smear microscopy
among adults suspected of having pulmonary TB. In
addition, we sought to determine the diagnostic ac-
curacy of TB-LAMP if used as an alternative test for
microscopy among adults with HIV infection or as an
add-on test for adults with negative sputum smear
microscopy results, and the proportion of indeter-
minate/invalid TB-LAMP results.
Methods
We followed standard guidelines and methods for sys-
tematic reviews and meta-analyses of diagnostic tests
[8]. We developed four PICO style research questions to
inform this review. First, what is the diagnostic accuracy
of TB-LAMP for detection of pulmonary TB in
reference to mycobacterial culture if used as an alterna-
tive test for sputum smear microscopy among all adults
and among HIV-infected adults? Second, what is the
diagnostic accuracy of TB-LAMP for detection of pul-
monary TB in reference to mycobacterial culture if used
as an add-on test among sputum smear-negative adults?
Third, what is the difference in diagnostic accuracy be-
tween TB-LAMP and Xpert for detection of pulmonary
TB in reference to mycobacterial culture among all
adults? And finally, what is the proportion of indeter-
minate/invalid results when TB-LAMP is used to detect
pulmonary TB among all adults and among
HIV-infected adults?
Search strategy
To perform a study of TB-LAMP, investigators must
order kits directly from Eiken. Therefore, a list of such
studies was requested from Eiken. To confirm the list
provided was complete, we performed a search in
Google Scholar and PubMed using the terms “TB
LAMP”, “TB-LAMP”, and “tuberculosis LAMP”. To
meet the deadline for WHO guideline development in
January 2016, we only included studies completed by
October 1, 2015.
Study and participant selection
We included all studies which 1) evaluated the Eiken
TB-LAMP kit on sputum samples from adult presump-
tive TB patients; 2) were conducted in an intermediate
or high TB burden country as defined by WHO; and 3)
were conducted after January 1, 2012 using the final
protocol, training, and TB-LAMP kits approved by
Eiken. We excluded studies that 1) did not exclude pa-
tients on TB treatment within 60 days of enrollment; 2)
did not perform speciation testing to confirm presence
of Mycobacterium tuberculosis (MTB) complex in posi-
tive cultures; or 3) performed TB-LAMP on frozen
specimens.
Authors of eligible studies provided individual partici-
pant data. We excluded individual participants who were
1) less than 18 years of age; 2) did not have results of
speciation testing for MTB; 3) had a positive culture but
speciation testing identified only non-tuberculous myco-
bacteria (NTM); 4) had a documented history of prior
TB; 5) had TB-LAMP testing performed on non-sputum
samples; 6) had TB-LAMP testing done with a total
reaction volume of < 25 μL; or 7) could not be classified
as TB-positive or TB-negative based on the reference
standard definitions described below. When comparing
TB-LAMP to Xpert, we also excluded individual
participants for whom Xpert was performed on frozen
samples or valid results were unavailable for both
TB-LAMP and Xpert.
Quality assessment
We used the Assessment of Diagnostic Accuracy Studies
(QUADAS-2) tool to assess the methodological quality
of eligible studies [9]. Specific yes/no signaling questions
were tailored for each QUADAS-2 domain.
Index tests
Studies recorded LAMP and Xpert results as negative,
positive or indeterminate/invalid in accordance with
manufacturer recommendations. We standardized spu-
tum smear microscopy results across studies by consid-
ering only direct ZN (Ziehl-Neelsen) and direct FM
(fluorescence microscopy) results, considering only the
first two smear results if more than two direct ZN or
direct FM results were available, and defining patients to
be sputum smear-positive if ≥1 acid-fast bacillus (AFB)
was identified in any sputum smear.
Reference standard
We used three hierarchical mycobacterial culture-based
reference standards to account for differences in the
number of cultures performed and results available. Pa-
tients were classified as having TB if one or more cul-
tures were positive and confirmed to be MTB complex
by speciation testing. Patients were classified as not
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having TB if there were no positive cultures and at least 1)
two negative cultures performed on different sputum sam-
ples (Standard 1); 2) two negative cultures performed on
one sputum sample (Standard 2); or 3) one negative cul-
ture (Standard 3). The three reference standards
allowed for a trade-off between yield of TB diagnosis
(highest with Standard 1 and lowest with Standard 3)
and number of studies/participants included in each
analysis (lowest with Standard 1 and highest with
Standard 3).
Statistical analysis
For all review questions, we assessed heterogeneity
visually with forest plots and statistically with the χ2
test for heterogeneity and the I2 test of inconsistency
[10, 11]. When four or more studies were available,
we generated pooled summary estimates of sensitivity/
specificity using hierarchical summary receiver operating
characteristic (HSROC) analysis. We plotted these
estimates along with 95% confidence regions in ROC
space. Pooled differences in sensitivity/specificity between
TB-LAMP and Xpert and pooled proportion of indeter-
minate/invalid TB-LAMP results were generated using
random effects meta-analysis. For the primary review
question of TB-LAMP accuracy if used as an alernative
test for smear microscopy, we explored potential reasons
for heterogeneity by performing sub-group analyses based
on the health system level (reference lab, microscopy cen-
ter, or hospital-affiliated clinics) at which the study was
conducted and study quality (high-quality studies across
all domains and within each domain of QUADAS-2).
Results
Of 20 studies identified by Eiken at the time of this
review, 13 met criteria for inclusion (Fig. 1): four
evaluation (EVAL) studies were conducted by the
Foundation for Innovative New Diagnostics (FIND) in
reference labs; one demonstration (DEMO) study was
Fig. 1 Study and participant selection flow diagram. Of 20 potentially eligible studies, 13 met study-level eligibility criteria. The 13 eligible studies
included 5099 participants, of whom 339 (7%) did not meet participant-level eligibility criteria. Of the 4760 eligible participants, 1810 (38%) were
included in the analysis for reference standard 1, 3110 (65%) for reference standard 2, and 4596 (97%) for reference standard 3. Abbreviations: TB,
Tuberculosis; MTB, Mycobacterium tuberculosis; μL, microliter
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conducted by FIND in a peripheral microscopy cen-
ter; seven studies were commissioned by FIND
through a request for applications (RFA); and one
study was sponsored by Eiken [12–14]. Authors of in-
cluded studies submitted individual data for 5099 par-
ticipants, of whom 4760 were eligible for analysis
(Additional file 1: Table S1).
Of the included studies, four were conducted at
reference laboratories, six at hospital and/or
university-affiliated clinics, and three at peripheral mi-
croscopy centers (Table 1). Study participants were
majority male with a median age of 40 (IQR 29–54)
years. More than 10% of participants were known to
be HIV-positive in four of 13 studies (S. Africa EVAL,
Malawi RFA, Uganda RFA, Ivory Coast RFA). The pro-
portion of patients with culture-positive TB was 20–
40% in most studies, but was notably lower (8–15%) in
three studies (India DEMO, India RFA, Vietnam RFA)
and higher (66%) in one study (Vietnam EVAL). The
proportion of patients with smear-negative TB ranged
widely from 13 to 59%.
Methodological quality
We considered overall risk of bias to be high due to
problems with the culture-based reference standard (all
13 studies), unclear patient selection (five studies), and
flow and timing concerns (eight studies) (Fig. 2). We
found applicability concerns to be low for index tests
and the reference standard; however, we judged five
studies to have high applicability concerns for patient se-
lection because they were conducted at referral labora-
tories/centers or because enrollment involved screening
of patients by a pulmonary specialist (Additional file 1:
Table S2).
TB-LAMP accuracy if used as an alternative test for smear
microscopy
Sensitivity of TB-LAMP in individual studies ranged
from 66 to 91% with Standard 1 (Fig. 3), 62–91%
with Standard 2 and 48–100% with Standard 3
(Additional file 1: Figure S1). We found significant
heterogeneity in sensitivity estimates, both from visual
inspection of forest plots and statistical testing (I2
72–94%, p < 0·003 for all reference standards). Pooled
sensitivity of TB-LAMP ranged from 77·7% (95% CI
71·2–83·0) when using Standard 1 to 80·3% (95% CI
70·3–87·5) when using Standard 3 (Table 2 and
Additional file 1: Figure S2). TB-LAMP was more
sensitive than sputum smear microcopy, with the sen-
sitivity difference ranging from 7·1% (95% CI 1·4–
12·9) when using Standard 1 to 13·2% (95% CI 4·5–
21·9) when using Standard 3.
Specificity of TB-LAMP in individual studies ranged
from 90 to 99% with Standard 1 (Fig. 3), and 90–100%
with Standards 2 and 3 (Additional file 1: Figure S1).
Visual inspection of forest plots indicated heterogeneity
in specificity estimates was less than for sensitivity esti-
mates, but was still significant (I2 61–78%, p < 0·03 for
all reference standards). Pooled specificity of TB-LAMP
ranged from 97·7% (95% CI 96·1–98·7) when using
Standard 3 to 98·1% (95% CI 95·7–99·2) when using
Standard 1 (Table 2 and Additional file 1: Figure S2).
TB-LAMP had similar specificity to sputum smear mi-
croscopy, with specificity difference ranging from − 1·8%
(95% CI -3·8–0·2) when using Standard 1 to − 1·3% (95%
CI -3·1% to + 0·4) when using Standard 3.
Sub-group analyses did not reduce heterogeneity in
pooled sensitivity and specificity estimates. Pooled sensi-
tivity was 78·0% (95% CI 68·9–85·0) among studies con-
ducted in reference labs and 86·8% (95% CI 67·9–95·4)
among studies conducted in hospital-affiliated clinics,
and there was significant heterogeneity within both
sub-groups (I2 74—96%, p < 0·01 for all reference stan-
dards) (Additional file 1: Table S3). Among studies rated
as high-quality for patient selection, pooled sensitivity
was 84·2% (95% CI 71·1–92·0) and pooled specificity
98·1% (95% CI 94·3–99·4), but there was significant het-
erogeneity across studies (I2 83%, p < 0·001 for sensitivity
and I2 87%, p < 0·001 for specificity). Pooled estimates
could not be obtained for studies conducted at micros-
copy centers and studies rated as high-quality for
reference standard because there were less than four
studies in these sub-groups.
TB-LAMP accuracy if used as an alternative test for smear
microscopy in HIV-infected adults
Pooled sensitivity of TB-LAMP was lower among
HIV-infected adults than all adults, ranging from
63·8% (95% CI 49·0–76·4) with Standard 2 to 73·4
(95% CI 51·9–87·6) with Standard 3 (Table 2 and
Additional file 1: Figure S3). Pooled specificity was
low with Standard 3 (95·0, 95% CI 64·0–99·5) but
high with Standard 2 (98·8, 95% CI 85·1–99·9). There
was considerable heterogeneity in sensitivity (I2 86%,
p < 0·001) and specificity (I2 86%, p < 0·001) estimates
with Standard 3, but not Standard 2 (I2 54%, p = 0·09 for
sensitivity and I2 0%, p = 0·42 for specificity) (Fig. 3). There
were insufficient studies (N = 2) to perform meta-analysis
using Standard 1.
TB-LAMP accuracy if used as an add-on test in smear-
negative adults
As expected, pooled sensitivity of TB-LAMP was lower
among smear-negative adults than among all adults,
ranging from 40·3% (95% CI 27·9–54·0) with Standard 3
to 42·2% (95% CI 27·9–57·9) with Standard 2 (Table 2
and Additional file 1: Figure S4). Pooled specificity of
TB-LAMP among smear-negative adults was similar to
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that observed among all adults, ranging from 97·7%
(95% CI 96·1–98·6) with Standard 3 to 98·4% (95% CI
95·9–99·4) with Standard 1. There was greater hetero-
geneity in sensitivity estimates than in specificity esti-
mates across studies (Fig. 3).
Comparison of diagnostic accuracy of TB-LAMP and Xpert
Xpert sensitivity across individual studies ranged from
65 to 97% between the three reference standards and
specificity ranged from 90 to 100% (Additional file 1:
Figure S5). TB-LAMP sensitivity ranged from 48 to
93% between reference standards, and specificity
ranged from 94 to 100% (Additional file 1: Figure S6).
The difference in sensitivity between TB-LAMP and
Xpert in individual studies ranged from − 14 to + 3%
for Standard 1, − 15 to + 3% for Standard 2, and − 36
to + 3% for Standard 3 (Additional file 1: Figure S7).
TB-LAMP had similar sensitivity compared to Xpert
using Standard 1 (pooled sensitivity difference − 2·5%
(95% CI -8·0 to + 2·9) but lower sensitivity when using
Standard 3 (− 6·9, 95% CI -12·8 to − 1·0) (Table 3). Dif-
ference in specificity between TB-LAMP and Xpert in
individual studies ranged from − 1 to + 3% for
Standard 1, − 1 to + 4% for Standard 2, and − 3 to + 5%
for Standard 3 (Additional file 1: Figure S8). There
was no difference in specificity of TB-LAMP and
Xpert regardless of reference standard used (Table 3).
Heterogeneity varied depending on the reference
standard used, with minimal heterogeneity in sensitivity
and specificity differences across studies with Standard 1,
and significant heterogeneity with Standard 3 (Additional
file 1: Figure S7 and Figure S8).
Indeterminate/invalid TB-LAMP results
The proportion of indeterminate TB-LAMP results was
0% in 11 studies and 1% in two studies (Additional file 1:
Figure S9). There was minimal heterogeneity across
studies (I2 28%, p = 0·25). Pooled proportion of
Fig. 2 Study quality assessment using QUADAS-2. Based on QUADAS-2 assessment, the risk of bias was judged to be unclear in 5 (38%) studies
due to patient selection issues, high for all studies due to an inadequate reference standard, and either high in 1 (8%) study or unclear in 7
studies (54%) due to flow and timing issues. In addition, applicability concerns were high in 5 (38%) studies due to patient selection issues
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indeterminate TB-LAMP results was < 0.1% (95% CI 0–0).
Results were similar among HIV-infected adults; pooled
proportion of indeterminate TB-LAMP results in this
sub-group was < 0.1% (95% CI 0–1).
Discussion
This systematic review identified 13 studies conducted
in intermediate to high TB burden countries evaluating
the accuracy of TB-LAMP performed directly on spu-
tum samples for diagnosis of pulmonary TB. TB-LAMP
had moderate sensitivity (pooled sensitivity 77·7, 95% CI
71·2–83·0) and high specificity (98·1, 95% CI 95·7–99·2)
when using the most stringent culture-based reference
standard. Sensitivity was lower among HIV-infected
adults (pooled sensitivity 63·8, 95% CI 49·0–76.4), likely
due to a higher proportion of smear-negative TB in this
population. Among all adults, TB-LAMP would identify
slightly less than half of all smear-negative TB patients
(pooled sensitivity 42·1, 95% CI 30·0–55·3) if used as an
add-on test following sputum smear microscopy. Diag-
nostic accuracy was comparable to that of Xpert, with
no significant differences in pooled sensitivity (− 2·5,
95% CI -8·0 to + 2·9) or pooled specificity (0·5, 95% CI
-0·9 to + 1·8) using the most stringent reference
standard. Finally, this review found indeterminate
TB-LAMP results were extremely uncommon (pooled pro-
portion < 0.1, 95% CI 0–0) (Additional file 1: Figure S9).
Overall, these data support a potential role for TB-LAMP
in the diagnosis of pulmonary TB in intermediate- to
high-burden countries where smear-microscopy is still the
predominant mode of TB diagnosis.
The target product profile for an alternative test for
smear microscopy recommends a sensitivity of at least
80% and specificity of at least 98% [15]. TB-LAMP very
nearly meets these criteria, although sensitivity was
below the recommended minimum of 60% for
smear-negative TB and 99% for smear-positive TB.
Nonetheless, TB-LAMP was consistently more sensitive
than sputum smear microscopy in individual studies,
and pooled sensitivity difference was 7·1%–13·2% in
favor of TB-LAMP depending on reference standard
used. Thus, it can be expected that use of TB-LAMP as
A
B
C
Fig. 3 Forest plots of TB-LAMP diagnostic accuracy, best reference standard. The figures show the sensitivity and specificity of TB-LAMP in
individual studies in reference to the best available reference standard for TB-LAMP as an alternative test for smear microscopy in all patients
(Panel 3A), TB-LAMP as an alternative test for smear microscopy in HIV-positive adults (Panel 3B), and TB-LAMP as an add-on test following smear
microscopy (Panel 3C). All reference standards classify patients as having TB if ≥1 positive culture was confirmed as M. tuberculosis by speciation
testing. To be classified as not having TB, patients were required to have no positive and at least 1) two negative cultures on two different
sputum specimens (Standard 1); or 2) two negative cultures on the same or different sputum specimens (Standard 2). Visual inspection of all
three forest plots indicates considerable heterogeneity in sensitivity estimates but less heterogeneity in specificity estimates
Shete et al. BMC Infectious Diseases          (2019) 19:268 Page 7 of 11
an alternative for sputum smear microscopy would lead
to more TB cases being identified while keeping
false-positive results to an acceptable minimum. As dis-
cussed further below, a better reference standard would
have likely further increased difference in sensitivity and
minimized any difference in specificity between
TB-LAMP and smear microscopy.
Although more accurate than microscopy, pooled sen-
sitivity of TB-LAMP is lower than has been reported for
Xpert (89, 95% CI 85–92] [16]. However, in
head-to-head comparisons, the sensitivity difference be-
tween TB-LAMP and Xpert was not statistically signifi-
cant except when using the least stringent reference
standard. Although more data is needed to confirm
whether TB-LAMP is as sensitive as Xpert, it is import-
ant to consider TB-LAMP has a different end-user pro-
file. It is less costly to deploy and has fewer
infrastructure requirements (e.g., stable power), but has
higher training requirements due to less automation.
Even if confirmed to be less sensitive than Xpert,
TB-LAMP may have a role at health centers that have
personnel with adequate technical skills but insufficient
resources or infrastructure to deploy Xpert. In addition,
the specificity of TB-LAMP was as high or higher than
that of Xpert, further supporting its use as an alternative
test for microscopy in settings without access to Xpert.
There are several limitations to the evidence identified
in this review. Most significantly, an inadequate refer-
ence standard was used across all studies, likely leading
to classification of patients with TB as not having TB.
With a better reference standard, it can be expected that
some false-positive TB-LAMP results would be
re-classified as true positives, leading to improved sensi-
tivity and specificity. Some true negative TB-LAMP re-
sults could also be re-classified as false negatives, leading
to lower sensitivity and specificity. Our findings suggest
the former is more likely, given that TB-LAMP specifi-
city improved with a more stringent reference standard
(i.e., when moving from Standard 3 to Standard 1). A
better reference standard may also have increased the
sensitivity difference while further minimizing the speci-
ficity difference observed between Xpert and TB-LAMP
due to the higher number of false-positive Xpert results.
Another key limitation is that the included studies may
not accurately reflect the introduction of TB-LAMP
under programmatic conditions. Only 3 studies were
conducted at peripheral health centers and Eiken pro-
vided extensive training to sites included in all studies.
Further operational research is needed to characterize
TB-LAMP performance under typical implementation
conditions as an alternative test for microscopy at per-
ipheral health centers. Finally, the data used in this ana-
lysis was taken from studies sponsored by either a
non-governmental organizations (NGOs) with interest in
the product or the manufacturer (Eiken), raising poten-
tial concerns about bias due to conflict of interest. To
overcome this limitation, this systematic review and
meta-analysis were the result of independent analysis of
individual level data taken from these studies. PICO
Table 2 Pooled sensitivity and specificity of TB-LAMP
Reference Standard Pooled Sensitivity Pooled Specificity
TB-LAMP accuracy if used as an alternative test for smear microscopy in
all adults
Standard 1a 77·7 (71·2–83·0) 98·1 (95·7–99·2)
Standard 2a 76·0 (69·9–81·2) 98·0 (96·0–99·0)
Standard 3a 80·3 (70·3–87·5) 97·7 (96·1–98·7)
TB-LAMP accuracy if used as an alternative test for smear microscopy in
HIV-positive adults
Standard 1a N/A (< 4 studies) N/A (< 4 studies)
Standard 2a 63·8 (49·0–76.4) 98·8 (85·1–99·9)
Standard 3a 73·4 (51·9–87·6) 95·0 (64·0–99·5)
TB-LAMP accuracy if used as an add-on test in smear-negative adults
Standard 1a 42·1 (30·0–55·3) 98·4 (95·9–99·4)
Standard 2a 42·2 (27·9–57·9) 98·0 (96·0–99·0)
Standard 3a 40·3 (27·9–54·0) 97·7 (96·1–98·6)
TB-LAMP accuracy in studies comparing to Xpertb
Standard 1a 78·0 (66·6–86·4) 98·9 (97·4–99·6)
Standard 2a 74·1 (64·1–82·2) 98·8 (96·8–99·6)
Standard 3a 75·8 (63·2–85·0) 98·2 (96·0–99·2)
Xpert accuracy in studies comparing to TB-LAMPb
Standard 1a 81·1 (70·6–88·5) 98·2 (95·9–99·2)
Standard 2a 80·4 (73·4–85·9) 97·4 (94·9–98·7)
Standard 3a 84·0 (75·6–90·0) 97·2 (94·4–98·6)
aAll reference standards classify patients as having TB if ≥1 positive culture
was confirmed as M. tuberculosis by speciation testing. To be classified as not
having TB, patients were required to have no positive and at least 1) two
negative cultures on two different sputum specimens (Standard 1); 2) two
negative cultures on the same or different sputum specimens (Standard 2); or
3) at least one negative culture (Standard 3)
bData restricted to study participants who had valid results for both TB-LAMP
and Xpert and testing performed on non-frozen specimens
Abbreviations: N/A not applicable
Table 3 TB-LAMP versus Xpert: Pooled Sensitivity and Specificity
differences
Reference
standard
Pooled sensitivity
differenceb
Pooled specificity
differenceb
Standard 1a -2·5 (− 8·0 to + 2·9) 0·5 (− 0·9 to + 1·8)
Standard 2a − 6·0 (− 12·1 to + 0·1) 1·0 (− 0·3 to + 2·4)
Standard 3a − 6·9 (− 12·8 to − 1·0) 1·1 (− 0·7 to + 2·8)
aAll reference standards classify patients as having TB if ≥1 positive culture
was confirmed as M. tuberculosis by speciation testing. To be classified as not
having TB, patients were required to have no positive and at least 1) two
negative cultures on two different sputum specimens (Standard 1); 2) two
negative cultures on the same or different sputum specimens (Standard 2); or
3) at least one negative culture (Standard 3)
bPositive difference favors TB-LAMP
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questions and reference standards were devised by the
authors in conjunction with the World Health
Organization as part of their guideline development
process.
In summary, this systematic review supports use of
TB-LAMP as a potential alternative test for smear mi-
croscopy for diagnosis of pulmonary TB in intermediate-
to high-burden countries, particularly in settings where
Xpert testing is not feasible. The results of this review
have influenced development of WHO guidelines related
to the use of TB-LAMP, which now conditionally rec-
ommend the use of TB-LAMP as an alternative test for
smear microscopy or as an add-on test for smear nega-
tive patients, but do not recommend its use in settings
where molecular testing such as Xpert is readily avail-
able [17]. However, additional studies following stan-
dardized protocols and including a high-quality
reference standard (liquid culture results on at least two
samples) are needed to better inform National TB Pro-
grammes of the relative performance of TB-LAMP ver-
sus Xpert in programmatic settings. Cost effectiveness
analysis conducted as part of WHO guideline develop-
ment on the use of TB-LAMP demonstrated lower per
test cost, operational costs, budgetary costs and favor-
able incremental cost effectiveness ratios compared to
Xpert in a few countries [18]. As with feasibility assess-
ments, additional cost and cost effectiveness analyses in
programmatic settings are required to further inform
context-specific uptake of TB-LAMP. The evidence to
date, along with increased automation and the ability to
identify rifampin resistance, suggests Xpert should re-
main the preferred diagnostic when sufficient financial
resources and infrastructure can support its use.
Conclusions
Although the performance of TB-LAMP has been evalu-
ated in several studies worldwide with variable results,
we report the first standardized evaluation of the results
of these individual studies to inform policy guidance.
The findings of our systematic review and meta-analysis
show that TB-LAMP has the potential to be a useful
diagnostic test for pulmonary TB, but that additional
high quality studies in programmatic conditions should
be done to strengthen the case for its use. TB-LAMP
performed better than sputum smear microscopy (more
sensitive and as specific) in the diagnosis of pulmonary
tuberculosis and performed similar to Xpert (similar
sensitivity and specificity). The results of this study pro-
vided the basis for the WHO’s guidelines on the use of
TB-LAMP for the diagnosis of pulmonary TB, which
recommend that TB-LAMP can be used as an alterna-
tive for microscopy for the diagnosis of pulmonary TB
in adults, and can be considered as an add-on test to mi-
croscopy particularly in sputum smear-negative adults
with TB symptoms in settings where Xpert testing is not
available and where drug-resistance or HIV co-infection
are not of concern [17].
Additional file
Additional file 1: Figure S1. Forrest plots of TB-LAMP diagnostic accuracy,
additional reference standards. The figures show the sensitivity and specificity
of TB-LAMP in individual studies in reference to all additional reference
standards not judged best available for TB-LAMP as an alternative test for
smear microscopy in all patients (Panel S1A and Panel S1B), TB-LAMP as an
alternative test for smear microscopy in HIV-positive adults (Panel S1C), and
TB-LAMP as an add-on test following smear microscopy (Panel S1D and Panel
S1E). All reference standards classify patients as having TB if ≥1 positive culture
was confirmed as M. tuberculosis by speciation testing. To be classified as not
having TB, patients were required to have no positive and at least 1) two
negative cultures on two different sputum specimens (Standard 1); 2) two
negative cultures on the same or different sputum specimens (Standard 2); or
3) at least one negative culture (Standard 3). Visual inspection of all three forest
plots indicates considerable heterogeneity in sensitivity estimates but less
heterogeneity in specificity estimates. Figure S2. TB-LAMP as an alternative for
sputum smear microscopy: Summary Receiver Operating Characteristic (SROC)
curves. The figure shows SROC curves for TB-LAMP (green line), individual
study estimates (grey circle), pooled estimates (red square), and the 95%
confidence region for pooled estimates (yellow dotted line) when using 3
culture-based reference standards. All reference standards classify patients as
having TB if ≥1positive culture was confirmed as M. tuberculosis by speciation
testing. To be classified as not having TB, patients were required to have no
positive and at least 1) two negative cultures on two different sputum
specimens (Standard 1); 2) two negative cultures on the same or
different sputum specimens (Standard 2); or 3) at least one negative
culture (Standard 3). Figure S3. TB-LAMP as an alternative test for
smear microscopy in HIV-positives: Summary Receiver Operating
Characteristic (SROC) curves. The figure shows SROC curves for TB-
LAMP (green line), individual study estimates (grey circle), pooled
estimates (red square), and the 95% confidence region for pooled
estimates (yellow dotted line) when using 2 culture-based reference
standards (no studies qualified for Standard 1). All reference standards
classify patients as having TB if ≥1positive culture was confirmed as
M. tuberculosis by speciation testing. To be classified as not having TB,
patients were required to have no positive and at least 1) two negative
cultures on the same or different sputum specimens (Standard 2); or 2)
at least one negative culture (Standard 3). Figure S4. TB-LAMP as an
add-on test following smear microscopy: Summary Receiver Operating
Characteristic (SROC) curves. The figure shows SROC curves for TB-
LAMP (green line), individual study estimates (grey circle), pooled
estimates (red square), and the 95% confidence region for pooled
estimates (yellow dotted line) when using 3 culture-based reference
standards. All reference standards classify patients as having TB if
≥1positive culture was confirmed as M. tuberculosis by speciation
testing. To be classified as not having TB, patients were required to
have no positive and at least 1) two negative cultures on two different
sputum specimens (Standard 1); 2) two negative cultures on the same
or different sputum specimens (Standard 2); or 3) at least one negative
culture (Standard 3). Figure S5. TB-LAMP vs. Xpert MTB/RIF: Forest plots
of Xpert MTB/RIF diagnostic accuracy. The figure shows forest plots of
Xpert MTB/RIF sensitivity and specificity in reference to 3 culture-based
reference standards for individual studies. All reference standards
classify patients as having TB if ≥1positive culture was confirmed as M.
tuberculosis by speciation testing. To be classified as not having TB,
patients were required to have no positive and at least 1) two negative
cultures on two different sputum specimens (Standard 1); 2) two
negative cultures on the same or different sputum specimens (Standard
2); or 3) at least one negative culture (Standard 3). Figure S6. TB-LAMP
vs. Xpert MTB/RIF: Forest plots of TB-LAMP diagnostic accuracy. The
figure shows forest plots of TB-LAMP sensitivity and specificity in
reference to 3 culture-based reference standards for individual studies.
All reference standards classify patients as having TB if ≥1positive
culture was confirmed as M. tuberculosis by speciation testing. To be
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classified as not having TB, patients were required to have no positive and at
least 1) two negative cultures on two different sputum specimens (Standard
1); 2) two negative cultures on the same or different sputum specimens
(Standard 2); or 3) at least one negative culture (Standard 3). Figure S7. TB-
LAMP vs. Xpert MTB/Rif: Forest plots of sensitivity difference. The figure shows
forest plots of the sensitivity difference between TB-LAMP and Xpert MTB/Rif®
for individual studies. The sensitivity of both tests was calculated in reference
to 3 culture-based reference standards. All reference standards classify patients
as having TB if ≥1positive culture was confirmed as M. tuberculosis
by speciation testing. To be classified as not having TB, patients were
required to have no positive and at least 1) two negative cultures on
two different sputum specimens (Standard 1); 2) two negative
cultures on the same or different sputum specimens; or 3) at least
one negative culture (Standard 3). Visual inspection of forest plots
and statistical testing indicate minimal heterogeneity with Standard 1
(I2 0%, p = 0.41), some heterogeneity with Standard 2 (I2 34%, p =
0.18), and significant heterogeneity with Standard 3 (I2 55%, p = 0.03).
Figure S8. TB-LAMP vs. Xpert MTB/Rif®: Forest plots of specificity
difference. The figure shows forest plots of the specificity difference
between TB-LAMP and Xpert MTB/Rif® for individual studies. The
specificity of both tests was calculated in reference to 3 culture-
based reference standards. All reference standards classify patients as
having TB if ≥1positive culture was confirmed as M. tuberculosis by
speciation testing. To be classified as not having TB, patients were re-
quired to have no positive and at least 1) two negative cultures on
two different sputum specimens (Standard 1); 2) two negative
cultures on the same or different sputum specimens (Standard 2); or
3) at least one negative culture (Standard 3). Visual inspection of forest plots
and statistical testing indicate minimal heterogeneity with Standard 1
(I2 28%, p = 0.25) and Standard 2 (I2 37%, p = 0.16), but significant
heterogeneity with Standard 3 (I2 72%, p = 0.001). Figure S9.
Proportion of indeterminate TB-LAMP results. The figure shows a
forest plot of the proportion of indeterminate TB-LAMP results
among all adults for individual studies. Visual inspection of forest
plots and statistical testing indicate minimal heterogeneity (I2 28%, p
= 0.25). Table S1. Patients included for analysis. Table S2. Signaling
questions for QUADAS-2 domains. Table S3. TB-LAMP as an alternative test
for smear microscopy: Exploration of heterogeneity. (DOCX 770 kb)
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